Home - Mesoblast Ltd
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care.
Aug 4, 2023 · Mesoblast intends to enroll adult patients at highest mortality risk with SR-aGVHD where existing therapy has not improved outcomes and 90-day survival remains as low as 20-30%. 1 Mesoblast has generated pilot data through its emergency IND program in adults showing a survival benefit with
Jul 23, 2024 · Mesoblast’s lead product candidate, Ryoncil ® (remestemcel-L), is an investigational therapy comprising culture expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor.
Mesenchymal Lineage Cells - Mesoblast Ltd
Mesoblast’s proprietary mesenchymal lineage adult stem cells (MLCs) are found in multiple tissues where they play vital roles in maintaining tissue health.
Overview - Mesoblast Ltd
Mesoblast is using its proprietary technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex diseases resistant to conventional standard of care and where inflammation plays a central role.
Dec 3, 2024 · Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its
Product Candidates Overview - Mesoblast Ltd
Mesoblast’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. Proprietary media formulations, advances in development of 3D bioreactor technology and automation are intended to …
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs.
Feb 28, 2023 · Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and lifethreatening inflammatory conditions. The Company has leveraged its proprietary -
Preliminary Final Report including Appendix 4E | Mesoblast
News Release. Preliminary Final Report including Appendix 4E. August 31, 2023 at 8:08 AM AEST. 9d61b6ab-8e07-4767-841f-c7bd25e9b880.pdf 4 MB. Investor Relations. At A Glance. Overview; Corporate Governance; Board of Directors; Management Team; Company Announcements. ASX Announcements; Share Price & Tools.